ClinicalTrials.gg
CompletedNCT06340854Updated Aug 11, 2026Results posted

A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes

A Phase 3 interventional study of Insulin icodec and Insulin glargine in Diabetes, Type 2, sponsored by Novo Nordisk A/S. Completed at 83 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
412
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 — 2 open to participants now, 2 under way, none of them phase 3. insulin icodec · Diabetes Mellitus, Type 2.

Enrollment
9th of 27
412 · median 84
Started
2024
with 1 other
Phase 3
9 of 27
none open now
Registered
25th of 27
by date
Lead sponsor
26 of 27
Novo Nordisk A/S

Among the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, this one is the 9th largest by enrollment, is one of 2 that started in 2024, is one of 9 in phase 3, and was the 25th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About insulin icodec

insulin icodec: first FDA approval 2026 (AWIQLI FLEXTOUCH), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes. Participants will either get insulin icodec or insulin glargine. Which treatment participants get is decided by chance. Insulin icodec is the new medicine being tested, while insulin glargine is already approved and can be prescribed by doctors. Participants will get one injection of insulin icodec once a week, or one injection of insulin glargine once a day, depending on the treatment group participants are assigned into. Participants will use a pen with a small needle to inject the medicine under participants skin into participants thigh, upper arm or stomach.The study will last for about 9 months, but participants will only be taking the study medicine for 6 months.

03

Conditions studied

  • Diabetes, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with T2D greater than equal to (≥) 180 days prior to the day of screening.
  • from 7.0-10.0% (53.0-85.8 mmol/mol), both inclusive, at screening confirmed by central laboratory analysis.
  • Treated with once-daily or twice-daily basal insulin (Neutral Protamine Hagedorn insulin, insulin degludec, insulin detemir, insulin glargine 100 U/mL, or insulin glargine 300 U/mL) ≥ 90 days prior to the day of screening with or without any of the following anti-diabetic drugs/regimens with stable doses greater than equal to (≥) 90 days prior to screening: metformin, sulfonylureas, meglitinides (glinides), Dipeptidyl peptidase 4 (DPP-4) inhibitors, Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors, thiazolidinediones, alphaglucosidase inhibitors, oral combination products (for the allowed individual oral anti- diabetic drugs), oral or injectable glucagon-like peptide 1 receptor agonists (GLP-1 RAs), injectable glucagon-like peptide 1(GLP-1)/ glucose-dependent insulinotropic polypeptide receptor agonist (GIP RA) combination products.
  • (BMI) ≤ 40.0 kilogram per square meter (kg/m\^2).

Exclusion criteria

Exclusion Criteria:

  • Any episodes of diabetic ketoacidosis within 90 days prior to the day of screening.
  • Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or within 180 days prior to the day of screening.
  • Chronic heart failure classified as being in Class IV at screening.
  • Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g., treatment with orlistat, thyroid hormones, or ).
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
412 participants (actual)

Study arms

  • Experimental
    Insulin icodec

    Participants will receive Insulin icodec subcutaneously once weekly.

    Drug: Insulin icodec · Drug: Insulin glargine

  • Active comparator
    Insulin glargine U100

    Participants will receive Insulin glargine subcutaneously once daily.

    Drug: Insulin icodec · Drug: Insulin glargine

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Glycated Haemoglobin (HbA1c)

    Change in HbA1c from week 0 to week 26 in percentage point is presented.

    Time frame: Week 0, Week 26

Secondary outcomes

  1. Change in Time in Range 3.9-10.0 Millimoles Per Litre (mmol/L) (70-180 Milligrams Per Decilitre (mg/dL))

    Change in time in range 3.9-10.0 mmol/L (70-180 mg/dL) from week -4-0 to week 22-26 is presented. Time in range is defined as 100 times the number of recorded measurements in glycaemic range 3.9-10.0 mmol/L (70-180 mg/dL), both inclusive, divided by the total number of recorded measurements.

    Time frame: week -4-0, week 22-26

  2. Change in DTSQs (Diabetes Treatment Satisfaction Questionnaire Status Version) Total Treatment Satisfaction

    Change in DTSQs total treatment satisfaction from week 0 to week 26 is presented. DTSQs measures the satisfaction with diabetes treatment regimens in people with diabetes. The measure consists of 8 items, of which 6 items contribute to 1 global score. Total Treatment Satisfaction score range is 0-36. 6 items scored on a scale of 0 to 6. The higher the score the greater the satisfaction with treatment.

    Time frame: week 0 to week 26

  3. Number of Severe Hypoglycaemic Episodes (Level 3)

    Number of severe hypoglycaemic episodes (level 3) from baseline (week 0) to week 31 is presented.

    Time frame: From baseline (week 0) to week 31

  4. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by Blood Glucose (BG) Meter)

    Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) from baseline (week 0) to week 31 is presented.

    Time frame: From baseline (week 0) to week 31

  5. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)

    Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3) from baseline (week 0) to week 31 is presented.

    Time frame: From baseline (week 0) to week 31

  6. Time Spent < 3.0 mmol/L (54 mg/dL)

    Time spent \< 3.0 mmol/L (54 mg/dL) during week 22 - 26 is presented. Time spent below threshold is defined as 100 times the number of recorded measurements below 3.0 mmol/L (54 mg/dL), divided by the total number of recorded measurements.

    Time frame: Week 22-26

  7. Change in Time Spent > 10.0 mmol/L (180 mg/dL)

    Change in time spent \> 10.0 mmol/L 180 mg/dL from week -4 - 0 to week 22-26 is presented. Time spent above threshold is defined as 100 times the number of recorded measurements above 10.0 mmol/L (180 mg/dL) divided by the total number of recorded measurements.

    Time frame: Week -4-0, Week 22-26

  8. Mean Weekly Insulin Dose

    Mean weekly insulin dose from week 24 to week 26 is presented.

    Time frame: From week 24 to week 26

  9. Change in Body Weight

    Change in body weight from baseline (week 0) to (week 26) is presented.

    Time frame: Week 0, Week 26

07

Results

Posted Jul 2, 2026

Participant flow

The trial was conducted at 66 sites in 8 countries.

Participant flow — Overall Study
MilestoneInsulin IcodecInsulin Glargine
Started206206
Full analysis set206206
Safety analysis set206206
Completed206203
Not completed03
Withdrew: Withdrawal by subject03

Outcome measures

PrimaryChange in Glycated Haemoglobin (HbA1c)

Change in HbA1c from week 0 to week 26 in percentage point is presented.

Time frame:
Week 0, Week 26
Reported as:
Mean · Percentage (%) point
Change in Glycated Haemoglobin (HbA1c)
Percentage (%) pointInsulin IcodecInsulin Glargine
Change in Glycated Haemoglobin (HbA1c)-0.84 ± 0.83-0.58 ± 0.89
Statistical analysis
  • Insulin Icodec vs Insulin Glargine · ANCOVA · p = <0.0001 · Treatment difference: -0.21 · 95% CI -0.36 to -0.07
SecondaryChange in Time in Range 3.9-10.0 Millimoles Per Litre (mmol/L) (70-180 Milligrams Per Decilitre (mg/dL))

Change in time in range 3.9-10.0 mmol/L (70-180 mg/dL) from week -4-0 to week 22-26 is presented. Time in range is defined as 100 times the number of recorded measurements in glycaemic range 3.9-10.0 mmol/L (70-180 mg/dL), both inclusive, divided by the total number of recorded measurements.

Time frame:
week -4-0, week 22-26
Reported as:
Mean · Percentage (%) of time
Change in Time in Range 3.9-10.0 Millimoles Per Litre (mmol/L) (70-180 Milligrams Per Decilitre (mg/dL))
Percentage (%) of timeInsulin IcodecInsulin Glargine
Change in Time in Range 3.9-10.0 Millimoles Per Litre (mmol/L) (70-180 Milligrams Per Decilitre (mg/dL))19.94 ± 20.4911.04 ± 19.43
SecondaryChange in DTSQs (Diabetes Treatment Satisfaction Questionnaire Status Version) Total Treatment Satisfaction

Change in DTSQs total treatment satisfaction from week 0 to week 26 is presented. DTSQs measures the satisfaction with diabetes treatment regimens in people with diabetes. The measure consists of 8 items, of which 6 items contribute to 1 global score. Total Treatment Satisfaction score range is 0-36. 6 items scored on a scale of 0 to 6. The higher the score the greater the satisfaction with treatment.

Time frame:
week 0 to week 26
Reported as:
Mean · Score on a scale
Change in DTSQs (Diabetes Treatment Satisfaction Questionnaire Status Version) Total Treatment Satisfaction
Score on a scaleInsulin IcodecInsulin Glargine
Change in DTSQs (Diabetes Treatment Satisfaction Questionnaire Status Version) Total Treatment Satisfaction3.94 ± 6.962.20 ± 5.94
SecondaryNumber of Severe Hypoglycaemic Episodes (Level 3)

Number of severe hypoglycaemic episodes (level 3) from baseline (week 0) to week 31 is presented.

Time frame:
From baseline (week 0) to week 31
Reported as:
Number · Episodes
Number of Severe Hypoglycaemic Episodes (Level 3)
EpisodesInsulin IcodecInsulin Glargine
Number of Severe Hypoglycaemic Episodes (Level 3)21
SecondaryNumber of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by Blood Glucose (BG) Meter)

Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) from baseline (week 0) to week 31 is presented.

Time frame:
From baseline (week 0) to week 31
Reported as:
Number · Episodes
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by Blood Glucose (BG) Meter)
EpisodesInsulin IcodecInsulin Glargine
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by Blood Glucose (BG) Meter)5370
SecondaryNumber of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)

Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3) from baseline (week 0) to week 31 is presented.

Time frame:
From baseline (week 0) to week 31
Reported as:
Number · Episodes
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)
EpisodesInsulin IcodecInsulin Glargine
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)5571
SecondaryTime Spent < 3.0 mmol/L (54 mg/dL)

Time spent \< 3.0 mmol/L (54 mg/dL) during week 22 - 26 is presented. Time spent below threshold is defined as 100 times the number of recorded measurements below 3.0 mmol/L (54 mg/dL), divided by the total number of recorded measurements.

Time frame:
Week 22-26
Reported as:
Mean · % of time
Time Spent < 3.0 mmol/L (54 mg/dL)
% of timeInsulin IcodecInsulin Glargine
Time Spent < 3.0 mmol/L (54 mg/dL)0.27 ± 0.480.23 ± 0.54
SecondaryChange in Time Spent > 10.0 mmol/L (180 mg/dL)

Change in time spent \> 10.0 mmol/L 180 mg/dL from week -4 - 0 to week 22-26 is presented. Time spent above threshold is defined as 100 times the number of recorded measurements above 10.0 mmol/L (180 mg/dL) divided by the total number of recorded measurements.

Time frame:
Week -4-0, Week 22-26
Reported as:
Mean · % of time
Change in Time Spent > 10.0 mmol/L (180 mg/dL)
% of timeInsulin IcodecInsulin Glargine
Change in Time Spent > 10.0 mmol/L (180 mg/dL)-20.54 ± 21.10-11.19 ± 19.94
SecondaryMean Weekly Insulin Dose

Mean weekly insulin dose from week 24 to week 26 is presented.

Time frame:
From week 24 to week 26
Reported as:
Geometric mean · Units of insulin/week
Mean Weekly Insulin Dose
Units of insulin/weekInsulin IcodecInsulin Glargine
Mean Weekly Insulin Dose278.45 ± 71.44270.19 ± 62.45
SecondaryChange in Body Weight

Change in body weight from baseline (week 0) to (week 26) is presented.

Time frame:
Week 0, Week 26
Reported as:
Mean · Kilogram (kg)
Change in Body Weight
Kilogram (kg)Insulin IcodecInsulin Glargine
Change in Body Weight2.04 ± 2.870.55 ± 3.16

Adverse events

Collected over From week 1 to week 31. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Icodec0/206 (0%)16/206 (7.8%)42/206 (20.4%)
Insulin Glargine0/206 (0%)12/206 (5.8%)30/206 (14.6%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventInsulin IcodecInsulin Glargine
Acute kidney injuryRenal and urinary disorders0/2062/206
PneumoniaInfections and infestations2/2062/206
Acquired oesophageal webGastrointestinal disorders0/2061/206
Alanine aminotransferase increasedInvestigations0/2061/206
Angina unstableCardiac disorders1/2060/206
Arthritis bacterialInfections and infestations0/2061/206
Aspartate aminotransferase increasedInvestigations0/2061/206
Atrial flutterCardiac disorders1/2060/206
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2060/206
Bronchitis bacterialInfections and infestations1/2060/206
Most frequent other events
Most frequent other events
EventInsulin IcodecInsulin Glargine
NasopharyngitisInfections and infestations28/20616/206
Diabetic retinopathyEye disorders6/20615/206
DiarrhoeaGastrointestinal disorders11/2064/206

Baseline characteristics

Full analysis set included all randomised participants.

Age, Continuous
Age, Continuous(Years)Insulin IcodecInsulin GlargineTotal
Mean62.41 ± 9.9162.52 ± 9.6562.47 ± 9.77
Sex: Female, Male
Sex: Female, Male(Participants)Insulin IcodecInsulin GlargineTotal
Female8490174
Male122116238
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Insulin IcodecInsulin GlargineTotal
Hispanic or Latino262753
Not Hispanic or Latino178175353
Unknown or Not Reported246
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Insulin IcodecInsulin GlargineTotal
American Indian or Alaska Native101
Asian6974143
Black or African American8816
White127122249
American Indian or Alaska Native, White011
Not reported112
08

Study locations

83 sites
  • Valley Research
    Fresno, California 93720, United States
  • Advanced Investigative Medicine, Inc.
    Hawthorne, California 90250, United States
  • Scripps Whittier Diabetes Inst
    La Jolla, California 92037, United States
  • Headlands Research CTR Lincoln
    Lincoln, California 95648, United States
  • Northeast Research Institute of Florida
    Fleming Island, Florida 32003, United States
  • South Broward Research LLC
    Miramar, Florida 33027, United States
  • Endo Res Solutions Inc
    Roswell, Georgia 30076, United States
  • Rocky Mountain Diab&Osteo Ctr
    Idaho Falls, Idaho 83404-7596, United States
  • Velocity Clinical_Valparaiso
    Valparaiso, Indiana 46383, United States
  • Iowa Diab & Endo Res Center
    West Des Moines, Iowa 50266, United States
  • Cotton-Oneill Diabetes and End
    Topeka, Kansas 66606-2806, United States
  • International Diabetes Center
    Minneapolis, Minnesota 55416, United States
  • Jefferson City Medical Group, PC
    Jefferson City, Missouri 65109, United States
  • Univ of Nebraska Medical CTR
    Omaha, Nebraska 68198-3020, United States
  • Palm Research Center Inc-Vegas
    Las Vegas, Nevada 89148, United States
  • Southern NH Diabetes and Endo_Nashua
    Nashua, New Hampshire 03060, United States
  • PharmQuest Life Sciences LLC
    Greensboro, North Carolina 27408, United States
  • Accellacare Wilmington
    Wilmington, North Carolina 28401, United States
  • Trial Management Associates
    Myrtle Beach, South Carolina 29572, United States
  • Amarillo Medical Specialists
    Amarillo, Texas 79124, United States
  • Velocity Clinical Res-Dallas
    Dallas, Texas 75230, United States
  • Diabetes and Thyroid Ctr of FW
    Fort Worth, Texas 76132, United States
  • Victorium Clinical Research
    Houston, Texas 77024, United States
  • PlanIt Research, PLLC
    Houston, Texas 77079, United States
  • Chrysalis Clinical Research
    St. George, Utah 84790, United States
  • Capital Clin Res Ctr,LLC
    Olympia, Washington 98502, United States
  • Rainier Clin Res Ctr Inc
    Renton, Washington 98057, United States
  • Medical Center Viva Feniks OOD
    Dobrich, 9300, Bulgaria
  • MHAT Knyaginya Klementina - Sofia EAD
    Sofia, 1233, Bulgaria
  • UMHAT Aleksandrovska EAD, Clinic of Endocrinology and Metabolic Diseases
    Sofia, 1431, Bulgaria
  • Medical Institute of Ministry of interior
    Sofia, 1606, Bulgaria
  • Medical Centre - Clinic Nova EOOD
    Varna, 9000, Bulgaria
  • MC Berbatov EOOD, Beli Drin
    Yambol, 8600, Bulgaria
  • InnoDiab Forschung GmbH
    Essen, 45136, Germany
  • Institut für Diabetesforschung GmbH Münster - Dr. med. Rose
    Münster, 48145, Germany
  • MedicalCenter am Clemenshospital - Schwerpunktpraxis für Diabetologie und Ernährungsmedizin
    Münster, 48153, Germany
  • RED-Institut für medizinische Forschung und Fortbildung GmbH
    Oldenburg in Holstein, 23758, Germany
  • Institut für Diabetesforschung Osnabrück
    Osnabrück, 49080, Germany
  • Zentrum für klinische Studien Allgäu Oberschwaben
    Wangen, 88239, Germany
  • Swasthya Diabetes Care
    Ahmedabad, Gujarat 390013, India
  • Lifecare Hospital and Research Centre
    Bangalore, Karnataka 560092, India
  • Belgaum Diabetes Centre
    Belagavi, Karnataka 590001, India
  • Manipal Hospital, Old Airport Road, Bengaluru
    Bengaluru, Karnataka 560017, India
  • Amrita Institute Of Medical Sciences & Research Centre
    Kochi, Kerala 682041, India
  • TOTALL Diabetes Hormone Institute
    Indore, Madhya Pradesh 452010, India
  • Seth GS Medical College & KEM Hospital
    Mumbai, Maharashtra 400012, India
  • Grant Medical Foundation Ruby Hall Clinic
    Pune, Maharashtra 411001, India
  • Chellaram Diabetes Institute
    Pune, Maharashtra 411021, India
  • Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)
    Puducherry, Tamil Nadu 605006, India
  • Gandhi Hospital & Medical college
    Hyderabad, Telangana 500003, India
  • Malla Reddy Narayana Multispeciality Hospital
    Hyderabad, Telangana 500055, India
  • FS Endocrine and diabetes Center
    Saidābād, Telangana 500059, India
  • Government Institute of Medical Sciences
    Noida, Uttar Pradesh 201310, India
  • Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh
    Chandigarh, 160012, India
  • Christian Medical College and Hospital
    Ludhiana, 141008, India
  • Heiwadai Hospital_Internal Medicine
    Miyazaki, Miyazaki 880-0034, Japan
  • Tokyo Medical Univ. Hospital_Diabetes, Metabolism and Endocrinology
    Shinjuku-ku, Tokyo, Tokyo 160-0023, Japan
  • Futata Tetsuhiro Clinic Meinohama_Internal medicine
    Fukuoka-shi, Fukuoka, 819-0006, Japan
  • Oyama East Clinic_Internal Medicine
    Tochigi, 323-0022, Japan
  • Noritake Clinic
    Ushiku-shi, Ibaraki, 300-1207, Japan
  • Uniwersytecki Szpital Kliniczny w Opolu
    Opole, Opole Voivodeship 45-401, Poland
  • NZOZ Specjalistyczny Osrodek Internistyczno-Diabetologiczny Małgorzata Arciszewska
    Bialystok, Podlaskie Voivodeship 15-435, Poland
  • NZOZ Vita-Diabetica Malgorzata Buraczyk
    Bialystok, Podlaskie Voivodeship 15-879, Poland
  • Centrum Medyczne Pratia Gdynia
    Gdynia, Pomeranian Voivodeship 81-338, Poland
  • NZOZ Euromedica Sp. z o.o.
    Grudziądz, 86-300, Poland
  • Centrum Medyczne Pratia Katowice
    Katowice, 40-081, Poland
  • Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
    Warsaw, 02-507, Poland
  • Trialmed CRS
    Piotrkow Trybunalski, Łódź Voivodeship 97-300, Poland
  • Advanced Clinical Research LLC
    Bayamón, 00959, Puerto Rico
  • Manati Ctr For Clin Research
    Manati, 00674, Puerto Rico
  • Medi-Clinic Bloemfontein
    Bloemfontein, Free State 9301, South Africa
  • Hemant Makan
    Johannesburg, Gauteng 1827, South Africa
  • Centre for Diabetes
    Johannesburg, Gauteng 2198, South Africa
  • Dr Moosa's Rooms
    Lenasia, Gauteng 1827, South Africa
  • Botho ke Bontle Health Services
    Pretoria, Gauteng 0184, South Africa
  • Dr A Amod
    Durban, KwaZulu-Natal 4092, South Africa
  • Dr MB Moosa's Practice
    Durban, KwaZulu-Natal 4092, South Africa
  • Dr Mahesh Duki Research And Trial Site
    Durban, KwaZulu-Natal 4339, South Africa
  • Hospital de Basurto
    Bilbao, Vizcaya 48013, Spain
  • Hospital Clinic i Provincial
    Barcelona, 08036, Spain
  • ABS La Roca CAP Vicenç_Endocrino
    La Roca Del Vallés, 08430, Spain
  • H. Clinico Univ. Virgen de la Victoria
    Málaga, 29010, Spain
  • H.U. Quirónsalud Madrid
    Pozuelo de Alarcón, 28223, Spain
09

References and documents

Publications

  • Rosenstock J, Mathieu C, Feinberg JB, Rao P, Scavenius C, Cheng AYY. Simplified Switching to Once-Weekly Insulin Icodec Without an Initial One-Time Additional Dose Versus Once-Daily Insulin Glargine U100 in Basal Insulin-Treated Type 2 Diabetes (ONWARDS 10): A Randomised Controlled Trial. Diabetes Obes Metab. 2026 May 21. doi: 10.1111/dom.70813. Online ahead of print. PubMed 42168822 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in May 2025, 12 months.

Results were first posted in Jul 2026, 1 year 1 month after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 12 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2024
First posted
Apr 2, 2024
StartActual
Apr 19, 2024
Primary completionActual
May 8, 2025
CompletionActual
Jun 13, 2025
Results first posted
Jul 2, 2026
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06340854
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 2, 2024
Start date
Apr 19, 2024
Primary completion
May 8, 2025
Completion
Jun 13, 2025
Results posted
Jul 2, 2026
Last update
Aug 11, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin icodec · Insulin Glargine

Start the discussion